<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0310211095
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RELVAR ELLIPTA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUTICASONE FUROATE,VILANTEROL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        158.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO OPERATION" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO OPERATION
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AK10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Relvar&nbsp; Ellipta contains two active ingredients; fluticasone furoate and vilanterol, to treat <strong>Asthma</strong> and <em>chronic obstructive pulmonary disease</em> <strong>(COPD).</strong> To take Relvar&nbsp; Ellipta, you breathe it into your lungs through your mouth using the Ellipta inhaler.</p><p>&nbsp;</p><p><strong>Relvar Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing</strong>. If you get this sort of attack you must use a quick-acting inhaler (such as salbutamol).</p><p>Fluticasone furoate belongs to a group of medicines called <em>corticosteroids</em>, often simply called <em>steroids</em>. Corticosteroids reduce inflammation. They reduce the swelling and irritation in the small air passages in the lungs and so ease breathing problems. Corticosteroids also help to prevent attacks of asthma.</p><p>&nbsp;</p><p>Vilanterol belongs to a group of medicines called <em>bronchodilators</em>. It relaxes the muscles of the small air passages in the lungs. This helps to open the airways and makes it easier for air to get in and out of the lungs. When it is taken regularly, it helps the small air passages to remain open.</p><p>When you take these two medicines together regularly, they will help to control your breathing difficulties.</p><p>&nbsp;</p><p><strong>Asthma</strong> is when the muscles surrounding the smaller airways become tight</p><p><em>(bronchoconstriction)</em>, swollen and irritated (<em>inflammation</em>). Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough.&nbsp;</p><p><strong>Chronic obstructive pulmonary disease </strong>(<strong>COPD</strong>) is when the airways become inflamed and thickened, usually due to smoking. It is a long-term condition that slowly gets worse.&nbsp; Symptoms include shortness of breath, cough, chest discomfort and coughing up mucus.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t use Relvar&nbsp; Ellipta&nbsp; </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to lactose or milk protein</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to fluticasone furoate, vilanterol or any other ingredients of Relvar Ellipta <em>(listed in Section 6).</em></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_14554" o:spid="_x0000_s1035"
 style='width:17.05pt;height:12.25pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="216408,155448" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_215" o:spid="_x0000_s1036" type="#_x0000_t75"
  style='position:absolute;width:216408;height:155448;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBKuBGLxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvQv9DeIIX0axCtWyNIkXBghW7Cl4fm9fdxc3LkkTd9tebguBxmJlvmNmiNbW4kvOVZQWjYQKC
OLe64kLB8bAevIHwAVljbZkU/JKHxfylM8NU2xt/0zULhYgQ9ikqKENoUil9XpJBP7QNcfR+rDMY
onSF1A5vEW5qOU6SiTRYcVwosaGPkvJzdjEKVn/76stOk1OfWp9t19O9230ulep12+U7iEBteIYf
7Y1WMB69wv+ZeATk/A4AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBKuBGLxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
">
  <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_216" o:spid="_x0000_s1037" style='position:absolute;
  left:108204;top:43;width:46619;height:206430;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
     8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
     style='mso-bidi-font-weight:normal'><span
     style='mso-spacerun:yes'> </span></b><span lang=EN-US><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="23" height="25" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><v:shape id="_x0000_i1029" type="#_x0000_t75" style='width:17.05pt;
 height:12.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp; If you think either of these applies to you,<strong> don&rsquo;t use Relvar Ellipta </strong>until you have checked with your doctor.</p><p><strong>Take special care with Relvar Ellipta&nbsp; </strong></p><p>Talk to your doctor before you use Relvar Ellipta:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>liver disease</strong>, as you may be more likely to have side effects, If you have moderate or severe liver disease, your doctor will limit your dose to the lower strength of Relvar Ellipta (100/25 micrograms once daily)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>heart problems</strong> or <strong>high blood pressure</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever been told you have <strong>diabetes</strong> or <strong>high blood sugar.</strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_263" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:17.5pt;
 height:12pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="23" height="16" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />&nbsp; <strong>Check with your doctor </strong>before you use Relvar Ellipta if you think any of these apply to you<strong>.&nbsp; </strong></p><p><strong>While you&rsquo;re using Relvar Ellipta </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_14702" o:spid="_x0000_s1032"
 style='width:17.05pt;height:12.35pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="216408,156777" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="Picture_x0020_278" o:spid="_x0000_s1033" type="#_x0000_t75"
  style='position:absolute;width:216408;height:155448;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_279" o:spid="_x0000_s1034" style='position:absolute;
  left:108204;top:1567;width:46619;height:206429;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
     8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
     style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
     style='mso-spacerun:yes'> </span></i></b><span lang=EN-US><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="23" height="24" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:17.05pt;
 height:12.35pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact your doctor</strong> if you experience <strong>blurred vision</strong> or other <strong>visual disturbances.<em> </em></strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_14703" o:spid="_x0000_s1029"
 style='width:17.05pt;height:12.35pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="216408,156777" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="Picture_x0020_291" o:spid="_x0000_s1030" type="#_x0000_t75"
  style='position:absolute;width:216408;height:155448;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_292" o:spid="_x0000_s1031" style='position:absolute;
  left:108204;top:1567;width:46619;height:206429;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
     8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
     style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
     style='mso-spacerun:yes'> </span></i></b><span lang=EN-US><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="23" height="24" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:17.05pt;
 height:12.35pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--><strong>&nbsp;&nbsp; Contact your doctor</strong> if you experience <strong>increased thirst, frequent urination</strong> or <strong>unexplained tiredness</strong> (signs of <strong>high blood sugar</strong>).<strong><em> </em></strong></p><p><strong>Immediate breathing difficulties&nbsp; </strong></p><p>If your breathing or wheezing gets worse straight after using Relvar&nbsp; Ellipta, stop using it, and get medical help immediately. <strong>&nbsp;</strong></p><p><strong>Other medicines and Relvar Ellipta&nbsp; </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription.</p><p>Some medicines may affect how Relvar Ellipta works, or make it more likely that you&rsquo;ll have side effects. These include:</p><p>&nbsp;&nbsp;&nbsp; &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, to treat <strong>fungal infections</strong>.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_14091" o:spid="_x0000_s1026"
 style='width:17.05pt;height:12.25pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="216408,155448" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="Picture_x0020_349" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;width:216408;height:155448;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_350" o:spid="_x0000_s1028" style='position:absolute;
  left:108204;top:43;width:46619;height:206429;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
     8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><span
     style='mso-spacerun:yes'> </span><span lang=EN-US><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="23" height="25" src="file:///C:/Users/aaa05057/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:17.05pt;
 height:12.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--><strong>&nbsp;&nbsp; Tell your doctor or pharmacist </strong>if you are taking this medicine.&nbsp; <strong>Pregnancy and breast-feeding&nbsp; </strong></p><p><strong>Relvar Ellipta is not usually recommended for use during pregnancy. </strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant or if you think you may be pregnant <strong>don&rsquo;t take Relvar&nbsp; Ellipta without asking your doctor</strong>. Your doctor will consider the benefit to you and the risk to your baby of taking Relvar Ellipta while you are pregnant.&nbsp;</p><p>&nbsp;</p><p>It is not known whether the ingredients of Relvar Ellipta can pass into breast milk. If you are breast-feeding, <strong>check with your doctor</strong> before you take Relvar Ellipta.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to use </strong></p><p><strong>Always use Relvar Ellipta exactly as your doctor has told you to.</strong> Check with your doctor, nurse or pharmacist if you&rsquo;re not sure.</p><p><strong>The usual dose </strong>of Relvar&nbsp; Ellipta for asthma and COPD is one inhalation 100 micrograms of fluticasone furoate and 25 micrograms of vilanterol) once daily at the same time each day.&nbsp;</p><p>If you have severe asthma, your doctor may decide that you should use one inhalation of the higher strength Relvar Ellipta inhaler (200 micrograms fluticasone furoate and 25 micrograms of vilanterol). This dose is also used once daily at the same time each day.</p><p><strong>&nbsp;</strong></p><p><strong>Use Relvar Ellipta regularly&nbsp; </strong></p><p>It is very important that you use Relvar Ellipta every day, as instructed by your doctor. This will help to keep you free of symptoms throughout the day and night.</p><p><strong>Relvar Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing</strong>. If you get this sort of attack you must use a quick-acting inhaler (such as salbutamol).</p><p>If you feel you are getting breathless or wheezy more often than normal, or if you are using your quick-acting inhaler more than usual, see your doctor.</p><p><strong>How to use the inhaler&nbsp; </strong></p><p>See <em>&lsquo;Step-by-step instructions&rsquo;</em> after section 6 of this leaflet for full information.</p><p>The first time you use Relvar Ellipta you do not need to check that the Ellipta inhaler is working properly &mdash; it is ready for use straight away.</p><p><strong>If you forget to use Relvar&nbsp; Ellipta&nbsp; </strong></p><p><strong>Don&#39;t take an extra dose to make up for a missed dose.</strong> Just take your next dose at the usual time.</p><p>If you become wheezy or breathless, or develop any other symptoms of an asthma attack, <strong>use your quick-acting inhaler</strong> (e.g. salbutamol<em>),</em> then seek medical advice.&nbsp;</p><p><strong>If you use too much Relvar Ellipta&nbsp; </strong></p><p>If you accidentally take a larger dose of Relvar Ellipta than your doctor has instructed, talk to your doctor or pharmacist. You may notice that your heart is beating faster than usual, you feel shaky or have a headache.&nbsp;</p><p>If you have used larger doses than instructed for a long period of time, it is particularly important that you ask your doctor or pharmacist for advice. This is because larger doses of Relvar Ellipta may reduce the amount of steroid hormones produced naturally by your body.&nbsp;</p><p><strong>Don&rsquo;t stop Relvar&nbsp; Ellipta without advice&nbsp; </strong></p><p>Use Relvar Ellipta for as long as your doctor recommends. It will only be effective as long as you are using it. Don&rsquo;t stop unless your doctor advises you to, even if you feel better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Relvar Ellipta can cause side effects, although not everybody gets them. Your doctor will consider the risk of side effects when deciding which strength of Relvar Ellipta you should use.</p><p><strong>Allergic Reactions&nbsp;&nbsp; </strong></p><p>Allergic reactions to Relvar Ellipta are rare (they affect less than 1 person in 1000).&nbsp;</p><p>If you have any of the following symptoms after taking Relvar Ellipta, <strong>stop</strong> <strong>taking this medicine</strong> and <strong>tell your doctor</strong> immediately.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (hives) or redness&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (angioedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; becoming very wheezy, coughing or having difficulty in breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suddenly feeling weak or light headed (may lead to collapse or loss of consciousness)</p><p><strong>Immediate breathing difficulties&nbsp; </strong></p><p>Immediate breathing difficulties after using Relvar Ellipta are rare (they affect less than 1 person in 1000)</p><p>If your breathing or wheezing gets worse straight after using Relvar Ellipta,<strong> stop using it immediately, </strong>and<strong> tell your doctor </strong>as soon as possible.</p><p>Infection of the lungs</p><p>Infection of the lungs (pneumonia) after using Relvar Ellipta are common (they may affect up to 1 in 10 people)</p><p><strong>Tell your doctor</strong> if you have any of the following while taking Relvar Ellipta &ndash; they could be symptoms of a lung infection&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever or chills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sputum production, change in sputum colour</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased cough or increased breathing difficulties <strong>Very Common side effects&nbsp; </strong></p><p>These may affect more than 1 in 10 people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common cold</p><p><strong>Common side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore, raised patches in the mouth or throat caused by a fungal infection (<em>candidiasis</em>). Rinsing your mouth out with water immediately after using Relvar&nbsp; Ellipta may help stop this side effect developing&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the lungs <em>(pneumonia) </em>(See earlier in <strong>Section 4</strong>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs (<em>bronchitis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the nose sinuses or throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu (<em>influenza</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain and irritation in the back of the mouth and throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the sinuses</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, runny or blocked nose&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voice disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain (<em>stomach pain</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakening of the bones, leading to fractures.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature (<em>fever</em>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p><strong>Uncommon side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 100</strong> people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in blood sugar (hyperglycaemia)</p><p>&nbsp;</p><p><strong>Rare side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 1,000</strong> people:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (<em>See earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immediate breathing difficulties and wheezing (See earlier in Section 4)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart beating faster (tachycardia).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; awareness of heart beat (palpitations)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>&nbsp;</p><p>➔ <strong>If you get any side effects, talk to your doctor, pharmacist or nurse.</strong><strong> This includes any possible side effects not listed in this leaflet. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep out of the sight and reach of children.&nbsp; </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take RELVAR ELLIPTA after the expiry date shown on the pack.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following removal from the tray, the product may be stored for a maximum period of 1 month, below 30&deg;C</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store RELVAR ELLIPTA below 30&deg;C.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you store in a refrigerator allow the inhaler to return to room temperature for at least an hour before use.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking RELVAR ELLIPTA, it is important to return any remnants which are left over to your pharmacist.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t throw away any medicines in wastewater or household waste.&nbsp; Ask your pharmacist how to throw away medicines no longer required.&nbsp; This will help to protect the environment.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Relvar Ellipta contains&nbsp; </strong></p><p>The active substances are 25 micrograms of vilanterol and 100 or 200 micrograms of fluticasone furoate.&nbsp;</p><p>Relvar Ellipta also contains lactose monohydrate (which contains milk proteins) and Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Relvar Ellipta is inhaled through the mouth using the Ellipta device. The active substances are in separate blisters in powder form inside the device. Relvar Ellipta contains either 14 or 30 doses. The 14 dose device has 14 blisters on each strip, and the 30 dose device has 30 blisters on each strip. 
The Ellipta device itself is a plastic inhaler with a light grey body, a pale blue or yellow mouthpiece cover and a dose counter. It is packaged in a foil laminate tray with a peelable foil lid. The tray contains a desiccant sachet, to reduce moisture in the packaging. Once you have opened the lid of the tray, throw the desiccant away — do not eat or inhale it.  
The step-by-step instructions shown below for the 30-dose (30 day supply) Ellipta inhaler also apply to the 14-dose (14 day supply) Ellipta inhaler. 


 

The inhaler is packaged in a tray. Do not open the tray until you are ready to inhale a dose of your medicine.  When you are ready to use your inhaler, peel back the lid to open the tray. The tray contains a desiccant sachet, to reduce moisture. Throw this desiccant sachet away — don’t open, eat or inhale it.
  

When you take the inhaler out of its box, it will be in the ‘closed’ position. Don’t open the inhaler until you are ready to inhale a dose of medicine. Write the “Discard by” date on the inhaler label in the space provided.

Read this before you start
	If you open and close the cover without inhaling the medicine, you will lose the dose. 
The lost dose will be securely held inside the inhaler, but it will no longer be available.
It is not possible to accidentally take extra medicine or a double dose in one inhalation.

7. 	Step-by-step instructions  
When you first use the Ellipta inhaler you do not need to check that it is working properly. 
 It is ready for use straight away, and you do not need to prepare it for use in any special way. Just follow these step-by-step instructions. Your Ellipta inhaler carton contains 
 
  
 
The inhaler is packaged in a tray. Do not open the tray until you are ready to inhale a dose of your medicine.  When you are ready to use your inhaler, peel back the lid to open the tray. The tray contains a desiccant sachet, to reduce moisture. Throw this desiccant sachet away — don’t open, eat or inhale it. 
  
 
When you take the inhaler out of its box, it will be in the ‘closed’ position. Don’t open the inhaler until you are ready to inhale a dose of medicine. Write the “Discard by” date on the inhaler label in the space provided. 
 
Read this before you start 
➔	If you open and close the cover without inhaling the medicine, you will lose the dose.  
The lost dose will be securely held inside the inhaler, but it will no longer be available. 
It is not possible to accidentally take extra medicine or a double dose in one inhalation. 
 
 
Prepare a dose  
➔	Wait to open the cover until you are ready to take your dose. Do not shake the inhaler. 
•	Slide the cover down until you hear a “click”. 
	 	 
Your medicine is now ready to be inhaled. 
The dose counter counts down by 1 to confirm. 
•	If the dose counter does not count down as you hear the “click”, the inhaler will not deliver medicine. Take it back to your pharmacist for advice. 
•	Do not shake the inhaler at any time 
 
Inhale your medication 
•	While holding the inhaler away from your mouth, breathe out as far as is comfortable. 
       Don’t breathe out into the inhaler. 
•	Put the mouthpiece between your lips, and close your lips firmly around it.       Don’t block the air vent with your fingers. 
 
•	Take one long, steady, deep breath in. Hold this breath for as long as possible (at least 3-4 seconds). 
•	Remove the inhaler from your mouth. 
•	Breathe out slowly and gently. 
 
➔	You may not be able to taste or feel the medicine, even when you are using the inhaler correctly. 
➔	If you want to clean the mouthpiece, use a dry tissue, before you close the cover. 
 
Close the inhaler and rinse your mouth. 
 
 
•	Slide the cover upwards as far as it will go, to cover the mouthpiece. 
 
  
 
•	Rinse your mouth with water after you have used the inhaler, if possible.  
      This will make it less likely that you will develop a sore mouth or throat as side effects. 
 
RELVAR and ELLIPTA are trademarks owned by or licenced to GSK group of companies. RELVAR ELLIPTA was developed in collaboration with Innoviva. 
©2022 GSK group of companies, all rights reserved. 










Prepare a dose 
	Wait to open the cover until you are ready to take your dose. Do not shake the inhaler.
•	Slide the cover down until you hear a “click”.








Your medicine is now ready to be inhaled.
The dose counter counts down by 1 to confirm.
•	If the dose counter does not count down as you hear the “click”, the inhaler will not deliver medicine. Take it back to your pharmacist for advice.
•	Do not shake the inhaler at any time

Inhale your medication
•	While holding the inhaler away from your mouth, breathe out as far as is comfortable.
       Don’t breathe out into the inhaler.
•	Put the mouthpiece between your lips, and close your lips firmly around it.
      Don’t block the air vent with your fingers.







•	Take one long, steady, deep breath in. Hold this breath for as long as possible (at least 3-4 seconds).
•	Remove the inhaler from your mouth.
•	Breathe out slowly and gently.

	You may not be able to taste or feel the medicine, even when you are using the inhaler correctly.
	If you want to clean the mouthpiece, use a dry tissue, before you close the cover.

Close the inhaler and rinse your mouth.


•	Slide the cover upwards as far as it will go, to cover the mouthpiece.

 

•	Rinse your mouth with water after you have used the inhaler, if possible. 
      This will make it less likely that you will develop a sore mouth or throat as side effects.

RELVAR and ELLIPTA are trademarks owned by or licenced to GSK group of companies.
RELVAR ELLIPTA was developed in collaboration with Innoviva.
©2020 GSK group of companies, all rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong>&nbsp;</p><p>Glaxo Operations UK Limited, Ware*, UK&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder: </strong>&nbsp;</p><p>Glaxo Saudi Arabia Limited, Jeddah*, Saudi Arabia&nbsp;</p><p>*member of the GlaxoSmithKline group of companies&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact: </strong>&nbsp;</p><p><strong>-GSK - Head Office, Jeddah </strong>&nbsp;</p><p>&bull;&nbsp;&nbsp; Tel: +966-12-6536666&nbsp;</p><p>&bull;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp; Email: <u>gcc.medinfo@gsk.com</u>&nbsp;</p><p>&bull;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/ &nbsp;&nbsp;</p><p>&bull;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia.</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>To report any side effect(s): </strong></p><p><strong><em>Kingdom of Saudi Arabia </em></strong></p><p><strong>-National Pharmacovigilance centre (NPC) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966 (12) 6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;P.O. Box 55850, Jeddah 21544, Saudi Arabia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong></p><p>- Medicament is a product which affects your health, and its consumption contrary to instructions are dangerous for you.</p><p>- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>- The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>- Do not by yourself interrupt the period of treatment prescribed for you.</p><p>- Do not repeat the same prescription without consulting your doctor.</p><p>- Keep all medicine out of reach of children</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: GDS12 
GDS Version Date: 27 May 2021

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ريلـﭭـار<sup> </sup>إليـﭙـتا<strong> </strong>يحتوي على مكونَين فعالَين؛ فلوتيكازون فيورويت وﭬـيلانتيرول، لعلاج <strong>الربو</strong> و<em>مرض الإنسداد الرئوي المزمن</em> <strong>(</strong><strong><u>C</u></strong><strong>hronic <u>O</u>bstructive <u>P</u>ulmonary <u>D</u>isease</strong><strong>). </strong>لتناول ريلـﭭـار<sup> </sup>إليـﭙـتا<strong>، </strong>يجب إستنشاقه داخل الرئتين عن طريق الفم بإستعمال جهاز الإستنشاق إليـﭙـتا<strong>.</strong></p><p dir="RTL"><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا لا يجوز إستعماله لتخفيف نوبة مفاجئة من ضيق التنفس أو الأزيز.</strong> إذا أصبت بهذا النوع من النوبات، يجب إستعمال جهاز الإستنشاق سريع المفعول (مثل السالبيوتامول).</p><p dir="RTL">فلوتيكازون فيورويت ينتمي إلى مجموعة من الأدوية تدعى <em>الكورتيكوستيرويدات</em>، غالباً ما تدعى <em>ستيرويدات</em>. الكورتيكوستيرويدات تخفف الإلتهاب. كما تخفف إلتهاب وتهيج المجاري الهوائية الدقيقة في الرئتين وبالتالي تخفف من حدة المشاكل بالتنفس.</p><p dir="RTL">الكورتيكوستيرويدات تساعد أيضاً على الوقاية من نوبات الربو.</p><p dir="RTL">ﭬـيلانتيرول ينتمي إلى مجموعة من الأدوية تُدعى <em>موسعات الشعب</em>. وهي ترخي عضلات المجاري الهوائية الدقيقة في الرئتين. وذلك يساعد على فتح المجاري الهوائية ويسهل دخول الهواء وخروجه من الرئتين. وعند تناوله بإنتظام، فهو يساعد المجاري الهوائية الدقيقة على البقاء مفتوحة.</p><p dir="RTL">عند تناول الدوائين معاً بإنتظام، ذلك يساعد على التحكم في صعوبات التنفس.</p><p dir="RTL"><strong>الربو</strong> يحدث عند تقلص العضلات المحيطة بالمجاري الهوائية الدقيقة <em>(تقلص الشعب الهوائية)</em>، وتورمها وتهيجها <em>(إلتهابها)</em>. الأعراض تأتي وتذهب ومن جملتها ضيق النفس، أزيز، ضيق الصدر وسعال.</p><p dir="RTL"><strong>مرض الإنسداد الرئوي المزمن (</strong><strong>COPD</strong><strong>)</strong> يحدث عندما تلتهب المجاري الهوائية وتصبح غليظة، نتيجةً للتدخين عادةً. وهي حالة طويلة الأمد تتدهور ببطء. الأعراض تشتمل على ضيق النفس، سعال، ضيق بالصدر وسعال مصحوب بمخاط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ا يجوز إستعمال</strong><strong> </strong><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت<strong> مصاباً بحساسية</strong> <em>(مفرط الحساسية)</em> لللاكتوز أو بروتين الحليب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت<strong> مصاباً بحساسية</strong> <em>(مفرط الحساسية)</em> لفلوتيكازون فيورويت، أو الـﭭـيلانتيرول، أو لأي من مكونات ريلـﭭـار<sup> </sup>إليـﭙـتا<strong> </strong>الأخرى <em>(المدرجة بالفقرة 6).</em></p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تظن أن أياً مما سبق ذكره ينطبق عليك، <strong>لا تستعمل ريلـﭭـار<sup> </sup>إليـﭙـتا </strong>إلا بعد الرجوع إلى الطبيب.</p><p dir="RTL"><strong>يجب توخي الحذر الشديد عند إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا<sup> </sup>في الحالات التالية</strong></p><p dir="RTL">يجب التحدث مع الطبيب قبل إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا في الحالات التالية:</p><p dir="RTL">إذا كنت<strong> مصاباً بمرض كبدي،</strong> نظراً لأنك قد تكون أكثر عرضة للإصابة بآثار جانبية. إذا كنت مصاباً بمرض كبدي معتدل أو شديد، سوف يحد طبيبك من الجرعة إلى أقل تركيز من ريلـﭭـار إليـﭙـتا (100/25 ميكروجرام مرة واحدة يوميا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشاكل قلبية</strong> أو <strong>ارتفاع ضغط الدم</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد اخبرت انك مصاب <strong>بالسكري</strong> أو <strong>سكر الدم مرتفع</strong>.</p><p dir="RTL"><strong>&not;</strong> &nbsp;&nbsp;&nbsp; <strong>يجب الرجوع إلى الطبيب</strong> قبل إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا إذا كنت تظن أن أياً مما سبق ذكره ينطبق عليك.</p><p dir="RTL"><strong>عند استخدم ريلـﭭـار<sup> </sup>إليـﭙـتا</strong></p><p dir="RTL"><strong>&not;</strong><strong> يجب إبلاغ الطبيب </strong>اذا كنت تعاني من <strong>عدم وضوح الرؤية</strong> أو <strong>اضطرابات بصرية</strong> أخرى.</p><p dir="RTL"><strong>&not;</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>إبلاغ</strong><strong> </strong><strong>الطبيب</strong><strong> </strong>اذا كنت تعاني من <strong>زيادة</strong><strong> </strong><strong>العطش</strong><strong> </strong><strong>،</strong><strong> </strong><strong>والتبول</strong><strong> </strong><strong>المتكرر</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>التعب</strong><strong> </strong><strong>الغير</strong><strong> </strong><strong>مبرر</strong> (جميعها علامات <strong>ارتفاع</strong><strong> </strong><strong>السكر</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الدم</strong>).</p><p dir="RTL"><strong>صعوبات بالتنفس بعد الاستخدام مباشرة </strong></p><p dir="RTL">في حالة تدهور التنفس أو الأزيز بعد إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا مباشرةً، يجب وقف إستعماله، والاستعانة بمساعدة طبية على الفور.<strong> </strong></p><p dir="RTL"><strong>الأدوية الأخرى و ريلـﭭـار<sup> </sup>إليـﭙـتا</strong></p><p dir="RTL">يجب إبلاغ الطبيب أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً أية أدوية أخرى. وذلك يشمل الأدوية التي يمكن الحصول عليها بدون وصفة طبية.</p><p dir="RTL">بعض الأدوية قد تؤثر على طريقة مزاولة ريلـﭭـار<sup> </sup>إليـﭙـتا لمفعوله، أو تجعلك أكثر عرضة للإصابة بآثار جانبية، من جملتها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، لعلاج <strong>العدوى الفطرية</strong>.</p><p dir="RTL"><strong>&not;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; يجب إبلاغ الطبيب</strong> <strong>أو الصيدلي</strong> إذا كنت تتناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا لا يوصى بإستعماله عادةً أثناء الحمل.</strong></p><p dir="RTL">إذا كنت حامل، أو تظنين أنك قد تكونين حامل، <strong>لا يجوز تناول ريلـﭭـار<sup> </sup>إليـﭙـتا</strong> <strong>دون الرجوع إلى الطبيب.</strong> سيضع الطبيب بعين الاعتبار المنفعة المتوقعة لك والمخاطر على طفلك الناتجة عن تناول ريلـﭭـار<sup> </sup>إليـﭙـتا أثناء الحمل.</p><p dir="RTL">ليس معروفاً ما إذا كانت مكونات ريلـﭭـار<sup> </sup>إليـﭙـتا قد تفرز في حليب الثدي.<strong> </strong>إذا كنت تقومين بالرضاعة الطبيعية، <strong>يجب الرجوع إلى الطبيب </strong>قبل تناول ريلـﭭـار<sup> </sup>إليـﭙـتا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الجرعة التي يجب إستعمالها</strong></p><p dir="RTL"><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا</strong> <strong>يجب إستعماله دائماً وفقاً لتعليمات الطبيب.</strong> يجب الرجوع إلى الطبيب، أو الممرضة، أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعة المعتادة</strong> من ريلـﭭـار<sup> </sup>إليـﭙـتا لعلاج الربو ومرض الإنسداد الرئوي المزمن (COPD) هي نشقة واحدة تحتوي على 100 ميكروجرام من فلوتيكازون فيورويت و25 ميكروجرام من الـﭭـيلانتيرول مرة واحدة يومياً في نفس الموعد كل يوم.</p><p dir="RTL">إذا كنت مصاباً بربو شديد، قد يقرر الطبيب أنك يجب أن تستعمل نشقة واحدة من ريلـﭭـار<sup> </sup>إليـﭙـتا للإستنشاق ذي التركيز الأعلى (200 ميكروجرام فلوتيكازون فيورويت و25 ميكروجرام ﭬـيلانتيرول). هذه الجرعة تعطى مرة واحدة يومياً في نفس الموعد كل يوم.</p><p dir="RTL"><strong>يجب إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا بإنتظام</strong></p><p dir="RTL">من المهم جداً إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا كل يوم، وفقاً لتعليمات الطبيب. ذلك سيساعد على إبقائك خالياً من الأعراض طوال النهار والليل.</p><p dir="RTL"><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا لا يجوز إستعماله لتخفيف نوبة مفاجئة من ضيق التنفس أو الأزيز.</strong> إذا أصبت بهذا النوع من النوبات، يجب إستعمال جهاز الإستنشاق سريع المفعول (مثل السالبيوتامول).</p><p dir="RTL">إذا شعرت أنك تعاني من ضيق التنفس أو الأزيز على نحو أكثر من الطبيعي، أو إذا كنت تستعمل جهاز الإستنشاق سريع المفعول أكثر من المعتاد، يجب مراجعة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إستعمال جهاز الإستنشاق </strong></p><p dir="RTL">انظر <em>&quot;تعليمات للاتباع خطوة بخطوة&quot;</em> في الفقرة 6 من هذه النشرة لكافة المعلومات.</p><p dir="RTL">عند إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا للمرة الأولى، لست بحاجة للتأكد من أن جهاز الإستنشاق إليـﭙـتا يعمل كما ينبغي - حيث أنه جاهز للإستعمال على الفور.</p><p dir="RTL"><strong>إذا نسيت إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا &nbsp;</strong></p><p dir="RTL"><strong>لا يجوز تناول جرعة إضافية لتعويض جرعة منسية.</strong> تناول جرعتك التالية فقط في موعدها المعتاد.</p><p dir="RTL">إذا أصبت بأزيز أو ضيق التنفس، أو ظهرت عليك أية أعراض أخرى لنوبة ربو، <strong>يجب إستعمال جهاز الإستنشاق سريع المفعول</strong> (على سبيل المثال: سالبيوتامول)، ثم استشارة الطبيب.</p><p dir="RTL"><strong>إذا استعملت أكثر مما يجب إستعماله من ريلـﭭـار<sup> </sup>إليـﭙـتا </strong></p><p dir="RTL">إذا تناولت بغير قصد جرعة أكبر من ريلـﭭـار<sup> </sup>إليـﭙـتا من الجرعة التي نصحك الطبيب بها، يجب التحدث مع الطبيب أو الصيدلي. قد تلاحظ أن قلبك يخفق أسرع من المعتاد، أو تشعر برعشة أو صداع.</p><p dir="RTL">إذا استعملت جرعات أكبر من الجرعة الموصوفة لك لفترة زمنية طويلة، من المهم جداً استشارة الطبيب أو الصيدلي. وذلك نظراً لأن الجرعات الأكبر من ريلـﭭـار<sup> </sup>إليـﭙـتا قد تسفر عن انخفاض كمية الهرمونات الستيرويدية التي ينتجها الجسم طبيعياً.</p><p dir="RTL"><strong>لا يجوز وقف إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا &nbsp;دون استشارة</strong></p><p dir="RTL">واصل إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا طوال المدة التي أوصى بها الطبيب. العقار سيكون فعالاً فقط طالما تستعمله.</p><p dir="RTL">لا يجوز وقف إستعمال العقار إلا إذا نصحك الطبيب بذلك، حتى إذا شعرت بتحسن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كشأن كافة الأدوية، ريلـﭭـار<sup> </sup>إليـﭙـتا قد يسبب آثاراً جانبية، إلا أنها لا تصيب كل فرد. الطبيب سيضع بعين الاعتبار خطر الإصابة بآثار جانبية عندما يقرر أي تركيز من ريلـﭭـار<sup> </sup>إليـﭙـتا يجب إستعماله.</p><p dir="RTL"><strong>تفاعلات تحسسية</strong></p><p dir="RTL">التفاعلات التحسسية تجاه ريلـﭭـار<sup> </sup>إليـﭙـتا تعد نادرة (تصيب أقل من شخص لكل 1000 شخص).</p><p dir="RTL">إذا كانت لديك أي من الأعراض التالية بعد تناول ريلـﭭـار<sup> </sup>إليـﭙـتا، <strong>توقف عن تناول هذا الدواء</strong> <strong>وأخبر طبيبك</strong> فوراً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (شرى) أو إحمرار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، يكون في بعض الأحيان في الوجه والفم (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يصبح الأزيز أو السعال شديداً أو توجد صعوبات في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فجأة تشعر بالضعف أو خفة الرأس (قد يؤدي إلى إنهيار أو فقدان الوعي)</p><p dir="RTL"><strong>صعوبات بالتنفس بعد الاستخدام مباشرة </strong></p><p dir="RTL">تعتبر صعوبات التنفس بعد استخدام ريلـﭭـار إليـﭙـتا مباشرة نادرة (تؤثر على أقل من شخص واحد من 1000).</p><p dir="RTL">في حالة تدهور التنفس أو الأزيز بعد إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا مباشرةً، <strong>يجب وقف إستعماله</strong> <strong>على الفور،</strong> و<strong>إبلاغ الطبيب</strong> في أسرع وقت ممكن.<strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>عدوى رئوية</strong></p><p dir="RTL">عدوى الرئتين (الالتهاب الرئوي) بعد استخدام ريلـﭭـار إليـﭙـتا شائعة (قد تؤثر على 1 من كل 10 أشخاص).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب إبلاغ الطبيب</strong> إذا كنت تعاني من أي مما يلي أثناء تناول ريلـﭭـار<sup> </sup>إليـﭙـتا - نظراً لأنها قد تكون أعراض عدوى رئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو رعاش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز البلغم، تغير لون البلغم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السعال أو زيادة الصعوبات بالتنفس.</p><p dir="RTL"><strong>آثار جانبية شائعة جداً</strong></p><p dir="RTL">هذه التأثيرات قد تصيب أكثر من فرد واحد من كل 10 أفراد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زكام.</p><p dir="RTL"><strong>آثار جانبية شائعة </strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 10 </strong>أفراد:<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع متقرحة، بارزة في الفم أو الحلق ناتجة عن عدوى فطرية <em>(داء المبيضات).</em> غسل الفم بالماء بعد إستعمال ريلـﭭـار<sup> </sup>إليـﭙـتا مباشرةً قد يساعد على وقف حدوث هذا الأثر الجانبي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى رئوية <em>(إلتهاب رئوي)</em> (انظر أعلاه في <strong>الفقرة 4</strong>).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب رئوي <em>(إلتهاب الشعب الهوائية).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأنف، أو الجيوب الأنفية أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلة برد <em>(إنفلونزا).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتهيج في الجزء الخلفي من الفم والحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب الجيوب الأنفية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، أو رشح أو إنسداد الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالصوت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن <em>(ألم بالمعدة)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العظام، مما يؤدي إلى كسور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة <em>(حمى)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شد عضلي.</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 100 </strong>فرد:<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم إنتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة سكر الدم (ارتفاع سكر الدم)</p><p dir="RTL"><strong>آثار جانبية نادرة</strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 1000 </strong>فرد:<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية (أنظر أعلاه الفقرة 4)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبات بالتنفس بعد الاستخدام مباشرة<strong> </strong>والصفير (أنظر أعلاه الفقرة 4)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب أسرع (تسارع ضربات القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بضربات القلب (خفقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأي من الآثار الجانبية، يجب التحدث مع الطبيب، أو الصيدلي أو الممرضة. وذلك يشمل أية آثار جانبية محتملة غير مدرجة في هذه النشرة.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يحفظ بعيداً عن متناول ونظر الأطفال.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريلـﭭـار إليـﭙـتا لا يجوز إستعماله بعد تاريخ انتهاء الصلاحية المبين على العبوة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد إزالة المغلف المعدني، يمكن حفظ المنتج لمدة أقصاها شهر في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ ريلـﭭـار إليـﭙـتا &nbsp;في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة حفظ العقار داخل الثلاجة، يجب إبقاء جهاز الإستنشاق لمدة ساعة واحدة على الأقل في درجة حرارة الغرفة قبل الإستخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف تناول ريلـﭭـار إليـﭙـتا ، فمن المهم إعادة أي كمية متبقية إلى الصيدلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنـزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد على وقاية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي </strong><strong>ريلـﭭـار<sup> </sup>إليـﭙـتا</strong></p><p dir="RTL">المواد الفعالة هي 25 ميكروجرام من الـﭭـيلانتيرول و100 أو 200 ميكروجرام من فلوتيكازون فيورويت.</p><p dir="RTL">ريلـﭭـار<sup> </sup>إليـﭙـتا<sup> </sup>يحتوي أيضاً على أحادي هيدرات لاكتوز (يحتوي على بروتينات الحليب) وسترات الماغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو</strong> <strong>ريلـﭭـار<sup> </sup>إليـﭙـتا</strong><strong> ومحتويات العبوة</strong></p><p dir="RTL">ريلـﭭـار<sup> </sup>إليـﭙـتا<sup> </sup>&nbsp;يستنشق عن طريق الفم بإستعمال جهاز إليـﭙـتا. المكونات الفعالة معبأة في فقاعات منفصلة على هيئة مسحوق داخل الجهاز. ريلـﭭـار<sup> </sup>إليـﭙـتا<sup> </sup>&nbsp;يحتوي إما على 14 أو 30 جرعة. الجهاز الذي يحتوي على 14 جرعة يوجد به 14 فقاعة في كل شريط، والجهاز الذي يحتوي على 30 جرعة يوجد به 30 فقاعة في كل شريط.</p><p dir="RTL">جهاز إليـﭙـتا نفسه هو عبارة عن جهاز الإستنشاق بلاستيكي ذي جسم لونه رمادي فاتح، وغطاء لقطعة الفم لونه أزرق فاتح أو أصفر وعداد للجرعات. وهو معبأ في وعاء مغلف برقاقة فضية ذات غطاء فضي قابل للنـزع. الوعاء به كيس يحتوي على <em>مجفف</em>، لتخفيض الرطوبة داخل العبوة. بمجرد فتح غطاء الوعاء، يجب التخلص من <em>المجفف</em> -&nbsp; ولا يجوز تناوله أو إستنشاقه.</p><p dir="RTL">التعليمات التي يجب اتباعها خطوة بخطوة المبينة أدناه لإستعمال جهاز الإستنشاق إليـﭙـتا الذي يحتوي على 30 جرعة(يكفي لثلاثين يوم ) &nbsp;تنطبق أيضاً على جهاز الإستنشاق إليـﭙـتا الذي يحتوي على 14 جرعة (يكفي لأربعة عشر يوم ).</p><p dir="RTL"><strong>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعليمات للاتباع خطوة بخطوة</strong></p><p dir="RTL">عند إستعمال جهاز الإستنشاق إليـﭙـتا للمرة الأولى، لست بحاجة للتأكد من أنه يعمل كما ينبغي - حيث أنه جاهز للإستعمال على الفور، ولست بحاجة لإعداده للإستعمال بأي طريقة خاصة. اتبع فقط التعليمات خطوة بخطوة.</p><p dir="RTL"><strong>يحتوي جهاز إستنشاق إليـﭙـتا الخاص بك على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='width:456.05pt;
 height:199.55pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="608" height="266" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p dir="RTL">جهاز الإستنشاق معبأ في وعاء <strong>لا تفتح الوعاء حتى تكون مستعدًا لاستنشاق جرعة من الدواء</strong>. عندما تكون مستعدًا لاستخدام جهاز الاستنشاق ، قم بإزالة الغطاء لفتح الوعاء.يحتوي الوعاء على كيس <strong>مجفف</strong>، لتخفيض الرطوبة. يجب التخلص من هذا الكيس-&nbsp; <strong>ولا يجوز فتحه</strong> او تناوله أو إستنشاقه.</p><p dir="RTL"><strong><em><!--[if gte vml 1]><v:shape id="Picture_x0020_4"
 o:spid="_x0000_i1026" type="#_x0000_t75" alt="img2.jpg" style='width:155pt;
 height:155pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title="img2"/>
</v:shape><![endif]--><img width="207" height="207" alt="img2.jpg" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" alt="Fig A" style='width:157.5pt;
 height:157.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title="Fig A"/>
</v:shape><![endif]--><img width="210" height="210" alt="Fig A" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند إخراج جهاز الإستنشاق من الوعاء المغلق، سيكون في وضع &quot;مغلق&quot;. <strong>لا يجوز فتح جهاز الاستنشاق</strong> <strong>إلا عندما تكون مستعداً لإستنشاق جرعة من الدواء</strong>. اكتب تاريخ &quot;التخلص&quot; على ملصق جهاز الاستنشاق في المساحة المتوفرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى قراءة التالي قبل البدء في الإستخدام</strong></p><p dir="RTL"><strong>&not;</strong><strong> في حالة فتح الغطاء وغلقه دون إستنشاق الدواء، ستفقد الجرعة.</strong></p><p dir="RTL">الجرعة المفقودة ستحفظ بأمان داخل جهاز الاسستنشاق، إلا أنها لن تكون متاحة بعد ذلك.</p><p dir="RTL">لا يمكن تناول كمية إضافية من الدواء أو جرعة مضاعفة بغير قصد في نشقة واحدة.</p><p dir="RTL"><!--[if gte vml 1]><v:group
 id="_x0000_s1036" style='position:absolute;left:0;text-align:left;
 margin-left:38.95pt;margin-top:14pt;width:442.25pt;height:353.75pt;z-index:251663360'
 coordorigin="1415,5619" coordsize="9377,7031">
 <v:shapetype id="_x0000_t32" coordsize="21600,21600" o:spt="32" o:oned="t"
  path="m,l21600,21600e" filled="f">
  <v:path arrowok="t" fillok="f" o:connecttype="none"/>
  <o:lock v:ext="edit" shapetype="t"/>
 </v:shapetype><v:shape id="_x0000_s1037" type="#_x0000_t32" style='position:absolute;
  left:7125;top:7273;width:7;height:1518;flip:x y' o:connectortype="straight"/>
 <v:shape id="_x0000_s1038" type="#_x0000_t32" style='position:absolute;left:7167;
  top:6064;width:2846;height:0;flip:x' o:connectortype="straight"/>
 <v:group id="_x0000_s1039" style='position:absolute;left:1415;top:5619;
  width:9377;height:7031' coordorigin="1423,5613" coordsize="9377,7031">
  <v:group id="_x0000_s1040" style='position:absolute;left:1423;top:5613;
   width:8624;height:7031' coordorigin="1423,5613" coordsize="8624,7031">
   <v:shape id="_x0000_s1041" type="#_x0000_t32" style='position:absolute;
    left:10013;top:6064;width:34;height:2569;flip:x y' o:connectortype="straight"/>
   <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
    <v:stroke joinstyle="miter"/>
    <v:path gradientshapeok="t" o:connecttype="rect"/>
   </v:shapetype><v:shape id="_x0000_s1042" type="#_x0000_t202" style='position:absolute;
    left:7167;top:5613;width:2549;height:2158;mso-width-relative:margin;
    mso-height-relative:margin' filled="f" fillcolor="#d8d8d8" stroked="f">
    <v:textbox style='mso-next-textbox:#_x0000_s1042'>
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;
       font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>الغطاء<o:p></o:p></span></b></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'>كل مرة تفتح فيها
       الغطاء، أنت تجهز جرعة واحدة من الدواء.</span><span lang=AR-SA
       style='font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'> </span><span
       lang=EN-US dir=LTR style='font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><v:shape id="_x0000_s1043" type="#_x0000_t202" style='position:absolute;
    left:1423;top:6700;width:5467;height:5944;mso-width-relative:margin;
    mso-height-relative:margin' filled="f" fillcolor="#d8d8d8" stroked="f">
    <v:textbox style='mso-next-textbox:#_x0000_s1043'>
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;
       font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>عداد
       الجرعات<o:p></o:p></span></b></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'>ذلك يبين عدد جرعات
       الدواء المتبقية في جهاز الإستنشاق.<o:p></o:p></span></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;
       font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>قبل إستعمال
       جهاز الإستنشاق، العداد يبين 30 جرعة بالضبط.<o:p></o:p></span></b></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'>ويقوم بالعد تنازلياً
       بمقدار <b>1</b> كل مرة تفتح فيها الغطاء.<o:p></o:p></span></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;
       font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>عندما
       تكون الجرعات المتبقية أقل من 10 جرعات، نصف عداد الجرعات سيظهر باللون
       الأحمر.<o:p></o:p></span></b></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'>بعد إستعمال آخر
       جرعة، <b>نصف عداد الجرعات سيظهر باللون الأحمر ويظهر الرقم صفر. </b>جهاز
       الإستنشاق أصبح فارغاً الآن.<o:p></o:p></span></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'>إذا فتحت الغطاء بعد
       ذلك، عداد الجرعات سيتغير لونه من نصف أحمر إلى أحمر كامل.<o:p></o:p></span></p>
       <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
       unicode-bidi:embed'><span lang=AR-SA style='font-size:16.0pt;font-family:
       "Traditional Arabic",serif;mso-bidi-language:AR-SA'><span
       style='mso-spacerun:yes'> </span></span><span lang=EN-US dir=LTR
       style='font-size:16.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><v:shape id="_x0000_s1044" type="#_x0000_t32" style='position:absolute;
    left:1423;top:7273;width:5702;height:0;flip:x' o:connectortype="straight"/>
  </v:group><v:shape id="Picture_x0020_2" o:spid="_x0000_s1045" type="#_x0000_t75"
   alt="Untitled.jpg" style='position:absolute;left:7016;top:7904;width:3784;
   height:4387;visibility:visible'>
   <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
    o:title="Untitled"/>
  </v:shape></v:group></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="591" height="475" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحضير الجرعة</strong></p><p dir="RTL"><strong>&not;</strong><strong> انتظر حتى تفتح الغطاء عندما تكون مستعداً لتناول الجرعة. لا يجوز رج جهاز الإستنشاق.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ادفع الغطاء باتجاه الأسفل حتى تسمع صوت &quot;طقطقة&quot;.</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:276.15pt;margin-top:2.6pt;width:71.45pt;height:29.25pt;
 z-index:251655168;mso-width-relative:margin;mso-height-relative:margin'
 filled="f" fillcolor="#d8d8d8" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1028'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-SA'>قطعة الفم</span></b><b><span
    lang=EN-US dir=LTR style='font-size:16.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="_x0000_s1029" type="#_x0000_t32" style='position:absolute;
 left:0;text-align:left;margin-left:272.5pt;margin-top:31.5pt;width:77.6pt;
 height:0;z-index:251656192' o:connectortype="straight"/><v:shape id="_x0000_s1030"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:277.5pt;margin-top:28.65pt;width:71.45pt;height:29.25pt;z-index:251657216;
 mso-width-relative:margin;mso-height-relative:margin' filled="f" fillcolor="#d8d8d8"
 stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1030'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><b><span lang=AR-SA style='font-size:16.0pt;font-family:
    "Traditional Arabic",serif;mso-bidi-language:AR-SA'>فتحة الهواء</span></b><b><span
    lang=EN-US dir=LTR style='font-size:16.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="_x0000_s1031" type="#_x0000_t32" style='position:absolute;
 left:0;text-align:left;margin-left:273.45pt;margin-top:58.7pt;width:77.6pt;
 height:0;z-index:251658240' o:connectortype="straight"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="106" height="77" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Picture_x0020_10" o:spid="_x0000_s1027"
 type="#_x0000_t75" alt="Untitled 2.jpg" style='position:absolute;left:0;
 text-align:left;margin-left:91.05pt;margin-top:17.25pt;width:238.75pt;
 height:193.35pt;z-index:-251662336;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg"
  o:title="Untitled 2"/>
</v:shape><![endif]--><img width="319" height="258" alt="Untitled 2.jpg" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg" /></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">الدواء أصبح الآن جاهزاً للإستعمال.</p><p dir="RTL">عداد الجرعات يقوم بالعد تنازلياً بمقدار <strong>1</strong> حتى تتأكد.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا لم يقم عداد الجرعات بالعد تنازلياً حتى تسمع صوت &quot;طقطقة&quot;، جهاز الإستنشاق لن يوصل الدواء. ويجب إعادته إلى الصيدلي لاستشارته.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا يجوز رج جهاز الإستنشاق في أي وقت.</strong></p><p dir="RTL"><strong>استنشق الدواء</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>وأنت ممسك بجهاز الإستنشاق بعيداً عن فمك، أطلق الزفير بقدر</strong><strong> </strong><strong>المستطاع دون</strong><strong> </strong><strong>مضايقة.</strong></p><p dir="RTL"><strong>لا يجوز</strong> إطلاق الزفير داخل جهاز الإستنشاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:group id="_x0000_s1033" style='position:absolute;
 left:0;text-align:left;margin-left:68.05pt;margin-top:19.05pt;width:406.35pt;
 height:219.9pt;z-index:251661312' coordorigin="1599,819" coordsize="8127,4456">
 <v:shape id="Picture_x0020_7" o:spid="_x0000_s1034" type="#_x0000_t75" alt="Ellipta_step3_diag"
  style='position:absolute;left:1599;top:819;width:8127;height:4456;
  visibility:visible'>
  <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png"
   o:title="Ellipta_step3_diag"/>
 </v:shape><v:shape id="_x0000_s1035" type="#_x0000_t202" style='position:absolute;
  left:6777;top:3114;width:2848;height:1358;mso-width-relative:margin;
  mso-height-relative:margin' stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1035'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
     unicode-bidi:embed'><b><span lang=AR-SA style='font-size:14.0pt;
     font-family:"Traditional Arabic",serif;mso-bidi-language:AR-SA'>شفتاك يجب
     أن تطبق على الشكل الكفافي لقطعة الفم للإستنشاق.</span></b><b><span
     lang=EN-US dir=LTR style='font-size:14.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="542" height="293" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image013.gif" /><strong>ضع قطعة الفم بين شفتيك، وأغلق شفتيك بإحكام حولها. لا</strong> تسد فتحة الهواء بأصابعك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>خذ نفساً طويلاً، بثبات وعمق. احبس هذا النفس لأطول مدة ممكنة (3-4 ثوانٍ على الأقل).</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أخرج جهاز الإستنشاق من فمك.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أطلق الزفير ببطء وبهدوء.</strong></p><p dir="RTL"><strong>&not;</strong><strong> </strong><strong>قد لا تستطيع تذوق الدواء أو الشعور به، حتى إذا كنت تستعمل جهاز الإستنشاق على نحو صحيح.</strong></p><p dir="RTL"><strong>&not;</strong><strong> </strong>إذا كنت تريد أن تنظف قطعة الفم، استعمل <strong>منديلاً جافاً، قبل</strong> إغلاق الغطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب إغلاق جهاز الإستنشاق وغسل الفم.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ادفع الغطاء باتجاه الأعلى حتى يتوقف، لتغطي قطعة الفم.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="Picture_x0020_4" o:spid="_x0000_s1032" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:154.7pt;margin-top:-6.7pt;width:249.65pt;
 height:258.7pt;z-index:-251657216;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image014.png"
  o:title=""/>
</v:shape><![endif]--><img width="333" height="345" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg" /></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يجب غسل الفم بالماء بعد إستعمال جهاز الإستنشاق اذا امكن.</strong></p><p dir="RTL">ذلك سيجعلك أقل عرضة للإصابة بقرحة بالفم أو الحلق كتأثير جانبي.</p><p dir="RTL"><strong><em>ريلـﭭـار<sup> </sup>و إليـﭙـتا</em></strong><sup> </sup>&nbsp;علامات&nbsp; تجارية مملوكة &nbsp;أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL"><strong><em>ريلـﭭـار<sup> </sup>و إليـﭙـتا</em></strong><sup> </sup>&nbsp;تم تطويره بالتعاون مع شركة انوڤيڤا.</p><p dir="RTL">&copy; 2020 مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسو أوپيريشنز المملكة المتحدة المحدودة.* وير، المملكة المتحدة.</p><p dir="RTL"><strong>تسويق:</strong></p><p dir="RTL">جلاكسو السعودية العربية المتحدة , جدة , المملكة العربية السعودية</p><p dir="RTL">* شركة تنتمي إلى مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL"><strong>للاستفسار عن أية معلومات عن هذا المستحضر الدوائي، يرجى الاتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">هاتف: 6536666 (12) 966 +</p><p dir="RTL">المحمول : 9882-904-56 &nbsp;966 +</p><p dir="RTL">البريد الإلكتروني : gcc.medinfo@gsk.com</p><p dir="RTL">الموقع الإلكتروني : https://gskpro.com/en-sa/</p><p dir="RTL">ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أية</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-205-11-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية. هاتف:2038222-11-966+ تحويلة:2340-2356-2317</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن:19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL"><strong>- </strong><strong>جلاكسو سميث كلاين </strong><strong>&ndash; </strong><strong>المكتب الرئيسي، جدة</strong><strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 (12) 966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحمول : 9882-904-56 &nbsp;966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL">- الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلانى الذى صرفها لك.</p><p dir="RTL">- فالطبيب و الصيدلانى هما الخبيران بالدواء، وبنفعه و ضرره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">- احتفظ بجميع الأدوية بعيداً عن متناول لأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	 رقم النص GDS:  12 	 	 	  	 	 	 	 	 تاريخ النص GDS: 27 مارس 2021 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RELVAR ELLIPTA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-dispensed dose contains either 100/25 micrograms or 200/25 micrograms of fluticasone furoate/vilanterol (as trifenatate).
Each single inhalation of fluticasone furoate/vilanterol provides a delivered dose of 92/22 micrograms of fluticasone furoate/vilanterol or 184/22 micrograms of fluticasone furoate/vilanterol.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ASTHMA</strong></p><p>RELVAR ELLIPTA is indicated for the maintenance treatment of asthma.</p><p><strong>COPD</strong></p><p>RELVAR ELLIPTA is indicated for the<strong> </strong>maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with an exacerbation history.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be regularly reassessed by a healthcare professional so that the strength of <strong><em>RELVAR ELLIPTA</em></strong>&nbsp;they are receiving remains optimal and is only changed on medical advice.</p><p><strong>ASTHMA</strong></p><p>Patients should be made aware that RELVAR ELLIPTA must be used regularly, even when asymptomatic.</p><p>If symptoms arise in the period between doses, an inhaled, short-acting beta<sub>2</sub>-agonist should be taken for immediate relief.</p><p>Patients should be regularly reassessed by a healthcare professional so that the strength of fluticasone furoate/vilanterol they are receiving remains optimal and is only changed on medical advice.</p><p><strong>Populations </strong></p><p>Adults and adolescents aged 12 years and over</p><p>The recommended dose of RELVAR ELLIPTA is:</p><p>One inhalation of RELVAR ELLIPTA 100/25 micrograms once daily</p><p>or</p><p>One inhalation of RELVAR ELLIPTA 200/25 micrograms once daily</p><p>A starting dose of RELVAR ELLIPTA 100/25 micrograms should be considered for patients who require a low to mid dose of inhaled corticosteroid in combination with a long acting beta<sub>2</sub>-agonist.</p><p>RELVAR ELLIPTA 200/25 micrograms should be considered for patients who require a higher dose of inhaled corticosteroid in combination with a long acting beta<sub>2</sub>-agonist.</p><p>If patients are inadequately controlled on RELVAR ELLIPTA 100/25 micrograms, consider increasing the dose to 200/25 micrograms, which may provide additional improvement in asthma control.</p><p><strong>Children</strong></p><p>The safety and efficacy of RELVAR ELLIPTA has not been established in children less than 12 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>COPD</strong></p><p><strong>Populations</strong></p><p>Adults</p><p>The recommended dose of RELVAR ELLIPTA is:</p><p>One inhalation of RELVAR ELLIPTA 100/25 micrograms once daily.</p><p>RELVAR ELLIPTA 200/25 micrograms is not indicated for patients with COPD.</p><p><strong>Children</strong></p><p>The use in children is not relevant given the COPD indication for this product.</p><p><strong>Special</strong><strong> population: Asthma and COPD</strong></p><p>Elderly</p><p>No dosage adjustment is required in patients over 65 years (see Pharmacokinetics &ndash; Special Patient Populations).</p><p>Renal impairment</p><p>No dose adjustment is required for patients with renal impairment (see Pharmacokinetics).</p><p>Hepatic Impairment</p><p>A clinical pharmacology study in subjects with mild, moderate and severe hepatic impairment showed up to 3-fold increase in systemic exposure to fluticasone furoate (AUC) (see Pharmacokinetics).</p><p>Caution should be exercised when dosing patients with hepatic impairment who may be more at risk of systemic adverse reactions associated with corticosteroids. For patients with moderate or severe hepatic impairment the maximum dose is 100/25&nbsp;micrograms (see Pharmacokinetics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RELVAR ELLIPTA is contraindicated in patients with severe milkprotein allergy or who have demonstrated hypersensitivity to either RELVAR ELLIPTA or any of the excipients. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Exacerbations</u></p><p>RELVAR ELLIPTA should not be used to treat acute asthma symptoms or an acute exacerbation in COPD, for which a short-acting bronchodilator is required.&nbsp; Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.</p><p>Patients should not stop therapy with RELVAR ELLIPTA, in asthma or COPD, without physician supervision since symptoms may recur after discontinuation.</p><p>Asthma-related adverse events and exacerbations may occur during treatment with RELVAR ELLIPTA. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of RELVAR ELLIPTA.</p><p><u>Paradoxical bronchospasm</u></p><p>As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.&nbsp; This should be treated immediately with a short-acting inhaled bronchodilator. RELVAR ELLIPTA should be discontinued immediately, the patient assessed, and alternative therapy instituted if necessary.</p><p><u>Cardiovascular effects</u></p><p>Cardiovascular effects, such as cardiac arrhythmias e.g. supraventricular tachycardia<strong> </strong>and extrasystoles may be seen with sympathomimetic drugs, including RELVAR ELLIPTA.<strong> </strong>In a placebo-controlled study in subjects with a history of, or an increased risk of, cardiovascular disease, there was no increase in the risk of, cardiovascular events, serious cardiovascular events, or adjudicated cardiovascular deaths in patients receiving fluticasone furoate/vilanterol compared with placebo (see Adverse Reactions). However,<strong> </strong>RELVAR ELLIPTA should be used with caution in patients with severe cardiovascular disease.</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>For patients with moderate to severe hepatic impairment, the 100/25&nbsp;micrograms dose should be used, and patients should be monitored for systemic corticosteroid-related adverse reactions (see Pharmacokinetics).</p><p><u>Systemic corticosteroid effects</u></p><p>Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include, HPA axis suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract glaucoma<strong> </strong>and central serous chorioretinopathy (CSCR).</p><p>As with all medication containing corticosteroids, RELVAR ELLIPTA should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections.</p><p><u>Hyperglycaemia</u></p><p>There have been reports of increases in blood glucose levels with fluticasone furoate/vilanterol. This should be considered in patients with a history of, or with risk factors for, diabetes mellitus (see Adverse Reactions).</p><p><u>Pneumonia</u></p><p>An increase in pneumonia has been observed in patients with COPD receiving RELVAR ELLIPTA. There was also an increased incidence of pneumonias resulting in hospitalisation. In some incidences these pneumonia events were fatal (see Clinical studies and Adverse Reactions). Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD receiving RELVAR ELLIPTA include current smokers, patients with a history of prior pneumonia, patients with a body mass index &lt;25 kg/m<sup>2 </sup>and patients with a (forced expiratory volume) FEV<sub>1</sub>&lt;50% predicted.&nbsp; These factors should be considered when fluticasone furoate/vilanterol is prescribed and treatment should be re-evaluated if pneumonia occurs.</p><p>Patients with asthma taking fluticasone furoate/vilanterol 200/25 micrograms may be at an increased risk of pneumonia compared with those receiving fluticasone furoate/vilanterol 100/25 or placebo (see Adverse Reactions). No risk factors were identified.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinically significant drug interactions mediated by fluticasone furoate or vilanterol at clinical doses are considered unlikely due to the low plasma concentrations achieved after inhaled dosing.</p><p><strong>Interaction with beta-blockers</strong></p><p>Beta-adrenergic blockers may weaken or antagonise the effect of beta<sub>2</sub>-adrenergic agonists. Concurrent use of both non-selective and selective beta-blockers should be avoided unless there are compelling reasons for their use.</p><p><strong>Interaction with CYP3A4 inhibitors</strong></p><p>Fluticasone furoate and vilanterol are both rapidly cleared by extensive first‑pass metabolism mediated by the liver enzyme CYP3A4.</p><p>Care is advised when co-administering with strong CYP 3A4 inhibitors (e.g. ketoconazole, ritonavir) as there is potential for an increased systemic exposure to both fluticasone furoate and vilanterol, which could lead to an increase in the potential for adverse reactions (see Pharmacokinetics).</p><p><strong>Interaction with P-glycoprotein inhibitors</strong></p><p>Fluticasone furoate and vilanterol are both substrates of P-glycoprotein (P-gp). A clinical pharmacology study in healthy subjects with co-administered vilanterol and the potent P-gp and moderate CYP3A4 inhibitor verapamil did not show any significant effect on the pharmacokinetics of vilanterol. Clinical pharmacology studies with a specific P-gp inhibitor and fluticasone furoate have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>There are no fertility data in humans.&nbsp; Animal studies showed no effect of vilanterol or fluticasone furoate on fertility (see Pre-Clinical Safety Data section).</p><p>Pregnancy</p><p>There has been limited pregnancy exposure in humans.</p><p>Animal studies have shown reproductive toxicity after administration of beta<sub>2</sub>-agonists and corticosteroids (see Pre-Clinical Safety Data section).</p><p>Administration of fluticasone furoate/vilanterol to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.</p><p>Lactation</p><p>There is limited<strong> </strong>information on the excretion of fluticasone furoate or vilanterol or their<strong> </strong>metabolites in human milk. However, other corticosteroids and beta<sub>2-</sub>agonists are detected in human milk (see Pre-Clinical Safety Data section). A risk to breastfed newborns/infants cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue RELVAR ELLIPTA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of RELVAR ELLIPTA on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology of fluticasone furoate or vilanterol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical trial data</strong></p><p>Data from large asthma and COPD clinical trials were used to determine the frequency of adverse reactions associated with RELVAR ELLIPTA. In the asthma clinical development program, a total of 7,034 patients were included in an integrated assessment of adverse reactions.&nbsp; In the COPD clinical development program, a total of 6,237 subjects were included in an integrated assessment of adverse reactions.</p><p>With the exception of pneumonia and fractures, the safety profile was similar in patients with asthma and COPD.&nbsp; During clinical studies, pneumonia and fractures were more frequently observed in patients with COPD.</p><p>These adverse reactions are listed by system organ class and frequency. The following convention has been used for the classification of adverse reactions:</p><p>&nbsp;</p><p>Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100 to &lt;1/10</p><p>Uncommon: &nbsp;&nbsp; &ge;1/1000 to &lt;1/100.</p><p>Rare&nbsp;&nbsp;&nbsp; &ge;1/10000 to &lt;1/1000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10000</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction(s)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia*,</p><p>Upper Respiratory Tract Infection,&nbsp;</p><p>Bronchitis, Influenza</p><p>Candidiasis of mouth and throat</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Extrasystoles**</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic &amp; mediastinal disorders</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p><p>Oropharyngeal pain,</p><p>Sinusitis, Pharyngitis<strong><em>,</em></strong></p><p>Rhinitis, Cough, Dysphonia</p></td><td style="vertical-align:top"><p>Very Common</p><p>Common</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia, Back pain</p><p>Fractures***</p></td><td style="vertical-align:top"><p>Common</p><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Description of selected adverse reactions</strong></p><p><u>*Pneumonia (see Warnings and Precautions)</u></p><p>In two replicate 12 month studies in a total of 3,255 patients with COPD (mean post-bronchodilator screening FEV<sub>1</sub> 45% of predicted, standard deviation (SD) 13%) who had experienced a COPD exacerbation in the previous year, there was a higher incidence of pneumonia (6%-7%) reported in patients receiving the fluticasone furoate (at strengths of 50, 100, and 200 micrograms)/vilanterol 25 micrograms combination than in those receiving vilanterol 25 micrograms alone (3%). Pneumonia which required hospitalisation occurred in 3% of patients receiving RELVAR ELLIPTA (all strengths) and in &lt;1% of patients receiving vilanterol.&nbsp; In these studies, nine fatal cases of pneumonia were reported.&nbsp; Of these, seven were reported during treatment with RELVAR ELLIPTA 200/25 micrograms, one during treatment with RELVAR ELLIPTA 100/25 micrograms and one post-treatment with vilanterol monotherapy.</p><p>In SUMMIT, a multi-centre, randomised study (HZC113782), 16,568 subjects received fluticasone furoate/vilanterol 100/25 micrograms, fluticasone furoate 100 micrograms, vilanterol 25 micrograms, or placebo for a mean of 1.7 years. Subjects had moderate COPD (mean post-bronchodilator screening FEV<sub>1</sub> 60% of predicted, SD 6%) and a history of, or an increased risk of, cardiovascular disease. The adverse events of pneumonia are noted in the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>On-treatment Events</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Subjects </strong></p><p><strong>[Event Rate Per 1000 Treatment Years]</strong></p></td></tr><tr><td style="vertical-align:top"><p>FF/VI 100/25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>FF 100</p><p>N=4,157</p></td><td style="vertical-align:top"><p>VI 25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=4,131</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>237 (6)</p><p>[39.5]</p></td><td style="vertical-align:top"><p>228 (5)</p><p>[42.4]</p></td><td style="vertical-align:top"><p>163 (4)</p><p>[27.7]</p></td><td style="vertical-align:top"><p>214 (5)</p><p>[38.4]</p></td></tr><tr><td style="vertical-align:top"><p>Serious pneumonia</p></td><td style="vertical-align:top"><p>140 (3)</p><p>[22.4]</p></td><td style="vertical-align:top"><p>146 (4)</p><p>[25.1]</p></td><td style="vertical-align:top"><p>104 (3)</p><p>[16.4]</p></td><td style="vertical-align:top"><p>127 (3)</p><p>[22.2]</p></td></tr><tr><td style="vertical-align:top"><p>Adjudicated pneumonia deaths</p></td><td style="vertical-align:top"><p>13 (&lt;1)</p><p>[1.8]</p></td><td style="vertical-align:top"><p>10 (&lt;1)</p><p>[1.5]</p></td><td style="vertical-align:top"><p>6 (&lt;1)</p><p>[0.9]</p></td><td style="vertical-align:top"><p>9 (&lt;1)</p><p>[1.4]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of pneumonia (adjusted for exposure, due to low numbers and limited number of patients on placebo) seen with RELVAR ELLIPTA 100/25 microgram strength (9.6/1000 patient years) was similar to placebo (8.0/1000 patient years).&nbsp; There was a higher incidence of pneumonia in the 200/25 microgram strength (18.4/1000 patient years) compared to the 100/25 microgram strength.&nbsp; Few of the pneumonia events led to hospitalisation with either strength, and there were no observed differences in the incidence of serious events between the two treatment strengths.</p><p><u>**Cardiovascular events (see Warnings and Precautions)</u></p><p><strong>For the SUMMIT study (see description above), cardiovascular adverse events are noted in the table below. </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>On-treatment Events</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Subjects</strong></p><p><strong>&nbsp;[Event Rate Per 1000 Treatment Years]</strong></p></td></tr><tr><td style="vertical-align:top"><p>FF/VI 100/25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>FF 100</p><p>N=4,157</p></td><td style="vertical-align:top"><p>VI 25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=4,131</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular</p></td><td style="vertical-align:top"><p>735 (18)</p><p>[163]</p></td><td style="vertical-align:top"><p>699 (17)</p><p>[157]</p></td><td style="vertical-align:top"><p>707 (17)</p><p>[157]</p></td><td style="vertical-align:top"><p>695 (17)</p><p>[164]</p></td></tr><tr><td style="vertical-align:top"><p>Serious cardiovascular</p></td><td style="vertical-align:top"><p>350 (8)</p><p>[64.5]</p></td><td style="vertical-align:top"><p>320 (8)</p><p>[58.1]</p></td><td style="vertical-align:top"><p>337 (8)</p><p>[59.2]</p></td><td style="vertical-align:top"><p>318 (8)</p><p>[63.2]</p></td></tr><tr><td style="vertical-align:top"><p>Adjudicated cardiovascular deaths</p></td><td style="vertical-align:top"><p>82 (2)</p><p>[11.7]</p></td><td style="vertical-align:top"><p>80 (2)</p><p>[11.6]</p></td><td style="vertical-align:top"><p>90 (2)</p><p>[12.9]</p></td><td style="vertical-align:top"><p>86 (2)</p><p>[13.0]</p></td></tr></tbody></table><p>&nbsp;</p><p><u>**Fractures </u></p><p>In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all RELVAR ELLIPTA groups (2%) compared with the vilanterol 25 micrograms group (&lt;1%). Although there were more fractures in the RELVAR ELLIPTA groups compared with the vilanterol 25 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in &lt;1% of the RELVAR ELLIPTA and vilanterol treatment arms.</p><p><strong>For the SUMMIT study (see description above), fractures are noted in the table below.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>On-treatment Events</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Subjects</strong></p><p><strong>&nbsp;[Event Rate Per 1000 Treatment Years]</strong></p></td></tr><tr><td style="vertical-align:top"><p>FF/VI 100/25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>FF 100</p><p>N=4,157</p></td><td style="vertical-align:top"><p>VI 25</p><p>N=4,140</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=4,131</p></td></tr><tr><td style="vertical-align:top"><p>All fractures</p></td><td style="vertical-align:top"><p>82 (2)</p><p>[13.6]</p></td><td style="vertical-align:top"><p>66 (2)</p><p>[12.8]</p></td><td style="vertical-align:top"><p>74 (2)</p><p>[13.2]</p></td><td style="vertical-align:top"><p>69 (2)</p><p>[11.5]</p></td></tr><tr><td style="vertical-align:top"><p>Fractures commonly associated with ICS use</p></td><td style="vertical-align:top"><p>23 (&lt;1)</p><p>[3.4]</p></td><td style="vertical-align:top"><p>24 (&lt;1)</p><p>[3.9]</p></td><td style="vertical-align:top"><p>17 (&lt;1)</p><p>[2.4]</p></td><td style="vertical-align:top"><p>13 (&lt;1)</p><p>[2.1]</p></td></tr></tbody></table><p>In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of fractures was &lt;1%, and usually associated with trauma.</p><p><strong>Post-marketing data</strong></p><p><strong><s>&nbsp;</s></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction(s)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria.</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations,</p><p>&nbsp;</p><p>Tachycardia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>&nbsp;</p><p>Rare</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Paradoxical bronchospasm</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>Kingdom of Saudi Arabia</strong></p><p><strong>-</strong>National Pharmacovigilance centre (NPC)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>-GSK - Head Office, Jeddah</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>saudi.safety@gsk.com&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://gskpro.com/en-sa/ </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>&nbsp;</strong></p><p><strong><em><u>For any information about this medicinal product, please contact:</u></em></strong><strong><em> </em></strong></p><p><strong><em>GSK - Head Office, Jeddah </em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Tel:&nbsp; +966-12-6536666 </em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Mobile: +966-56-904-9882 </em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Email: <u>gcc.medinfo@gsk.com</u>&nbsp;&nbsp; </em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Website: </em></strong><strong><em>https://gskpro.com/en</em></strong><strong><em>-</em></strong><strong><em>sa/</em></strong><strong><em> </em></strong></p><p><strong><em>P.O. Box 55850, Jeddah 21544, Saudi Arabia</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and signs</p><p>There are no data available from clinical trials on overdose with RELVAR ELLIPTA.</p><p>An overdose of RELVAR ELLIPTA may produce signs and symptoms due to the individual components&rsquo; actions, including those seen with overdose of other beta<sub>2</sub>‑agonists and consistent with the known inhaled corticosteroid class effects (see Warnings and Precautions).</p><p>Treatment</p><p>There is no specific treatment for an overdose with RELVAR ELLIPTA. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p><p>Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. Cardioselective beta-blocking drugs should be used with caution in patients with a history of bronchospasm.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of action</p><p>Fluticasone furoate and vilanterol represent two classes of medications (a synthetic corticosteroid and a selective, long-acting beta<sub>2</sub>-receptor agonist).</p><p>Pharmacodynamic effects</p><p><u>Fluticasone furoate: </u></p><p>Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti inflammatory activity. The precise mechanism through which fluticasone furoate affects asthma and COPD symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g. eosinophils, macrophages, lymphocytes) and mediators (e.g. cytokines and chemokines involved in inflammation).</p><p><u>Vilanterol trifenatate:</u></p><p>Vilanterol trifenatate is a selective long-acting, beta<sub>2</sub>-adrenergic agonist (LABA).</p><p>The pharmacologic effects of beta<sub>2</sub>-adrenoceptor agonist drugs, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3&rsquo;,5&rsquo;-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.</p><p>Molecular interactions occur between corticosteroids and LABAs, whereby steroids activate the beta<sub>2</sub>-receptor gene, increasing receptor number and sensitivity; and LABAs prime the glucocorticoid receptor for steroid-dependent activation and enhance cell nuclear translocation. These synergistic interactions are reflected in enhanced anti-inflammatory activity, which has been demonstrated in vitro and in vivo in a range of inflammatory cells relevant to the pathophysiology of both asthma and COPD.</p><p>In peripheral blood mononuclear cells from subjects with COPD, a larger anti-inflammatory effect was seen in the presence of the combination of fluticasone furoate/vilanterol compared with fluticasone furoate alone at concentrations achieved with clinical doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>The absolute bioavailability for fluticasone furoate and vilanterol when administered by inhalation as RELVAR ELLIPTA was on average 15.2% and 27.3%, respectively. The oral bioavailability of both fluticasone furoate and vilanterol was low, on average 1.26% and &lt;2%, respectively. Given this low oral bioavailability, systemic exposure for fluticasone furoate and vilanterol following inhaled administration is primarily due to absorption of the inhaled portion of the dose delivered to the lung.</p><p>Distribution</p><p>Following intravenous dosing, both fluticasone furoate and vilanterol are extensively distributed with average volumes of distribution at steady state of 661&nbsp;L and 165&nbsp;L, respectively.</p><p>Both fluticasone furoate and vilanterol have a low association with red blood cells. In vitro plasma protein binding in human plasma of fluticasone furoate and vilanterol was high, on average &gt;99.6% and 93.9%, respectively. There was no decrease in the extent of in vitro plasma protein binding in subjects with renal or hepatic impairment.</p><p>Fluticasone furoate and vilanterol are substrates for P-gp, however, concomitant administration of fluticasone furoate/vilanterol with P-gp inhibitors is considered unlikely to alter fluticasone furoate or vilanterol systemic exposure since they are both well absorbed molecules.</p><p><strong>Metabolism</strong></p><p>Based on in vitro data, the major routes of metabolism of both fluticasone furoate and vilanterol in human are mediated primarily by CYP3A4.</p><p>Fluticasone furoate is primarily metabolised through hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity.</p><p>Vilanterol is primarily metabolised by O‑dealkylation to a range of metabolites with significantly reduced b<sub>1</sub>- and b<sub>2</sub>-agonist activity.</p><p>A repeat dose CYP3A4 drug interaction study was performed in healthy subjects with the fluticasone furoate/vilanterol combination (200/25) and the strong CYP3A4 inhibitor ketoconazole (400mg).&nbsp; Co-administration increased mean fluticasone furoate AUC<sub>(0‑24)</sub> and C<sub>max </sub>by 36% and 33%, respectively.&nbsp; The increase in fluticasone furoate exposure was associated with a 27% reduction in 0-24 h weighted mean serum cortisol.&nbsp;</p><p>Co-administration increased mean vilanterol AUC<sub>(0-t)</sub> and C<sub>max</sub> 65% and 22%, respectively.&nbsp; The increase in vilanterol exposure was not associated with an increase in beta-agonist related systemic effects on heart rate, blood potassium or QTcF interval.</p><p><strong>Elimination</strong></p><p>Following oral administration, fluticasone furoate was eliminated in humans mainly by metabolism with metabolites being excreted almost exclusively in faeces, with &lt;1% of the recovered radioactive dose eliminated in the urine. The apparent plasma elimination half-life of fluticasone furoate following inhaled administration of fluticasone furoate/vilanterol was, on average, 24&nbsp;hours.</p><p>Following oral administration, vilanterol was eliminated in humans mainly by metabolism followed by excretion of metabolites in urine and faeces approximately 70% and 30% of the radioactive dose respectively. The apparent plasma elimination half-life of vilanterol following inhaled administration of fluticasone furoate/vilanterol was, on average, 2.5&nbsp;hours.</p><p>Special Patient Populations</p><p>Population PK meta-analyses for fluticasone furoate and vilanterol were conducted in phase III studies in subjects with asthma or COPD. The impact of demographic covariates (age, gender, weight, BMI, racial group, ethnicity) on the pharmacokinetics of fluticasone furoate and vilanterol were evaluated as part of the population pharmacokinetic analysis.</p><p>Race</p><p>In subjects with asthma or COPD estimates of fluticasone furoate AUC<sub>(0-24)</sub> for East Asian, Japanese and South East Asian subjects (12-14% subjects) were up to 53% higher on average compared with Caucasian subjects. However, there was no evidence for the higher systemic exposure in these populations to be associated with greater effect on 24&nbsp;hour urinary cortisol excretion. There was no effect of race on pharmacokinetic parameter estimates of vilanterol in subjects with COPD.</p><p>On average, vilanterol C<sub>max</sub> is estimated to be 220 to 287% higher and AUC<sub>(0-24)</sub> comparable for those subjects from an Asian heritage compared with subjects from other racial groups. However, there was no evidence that this higher vilanterol C<sub>max </sub>resulted in clinically significant effects on heart rate.</p><p>Children</p><p>In adolescents (12 years or older), there are no recommended dose modifications.</p><p>The pharmacokinetics of fluticasone furoate/vilanterol in patients less than 12 years of age has not been studied. The safety and efficacy of fluticasone furoate/vilanterol in children under the age of 12 years has not yet been established.</p><p>Elderly</p><p>The effects of age on the pharmacokinetics of fluticasone furoate and vilanterol were determined in phase III studies in COPD and asthma.</p><p>There was no evidence for age (12-84) to affect the PK of fluticasone furoate and vilanterol in subjects with asthma.</p><p>There was no evidence for age to affect the PK of fluticasone furoate in subjects with COPD while there was an increase (37%) in AUC <sub>(0-24)</sub> of vilanterol over the observed age range of 41 to 84&nbsp;years. For an elderly subject (aged 84&nbsp;years) with low bodyweight (35&nbsp;kg) vilanterol AUC <sub>(0-24)</sub> is predicted to be 35% higher than the population estimate (subject with COPD aged 60&nbsp;years and bodyweight of 70&nbsp;kg), whilst C<sub>max</sub> was unchanged. These differences are unlikely to be of clinical relevance.</p><p>Renal impairment</p><p>A clinical pharmacology study of fluticasone furoate/vilanterol showed that severe renal impairment (creatinine clearance &lt;30mL/min) did not result in significantly greater exposure to fluticasone furoate or vilanterol or more marked corticosteroid or beta<sub>2</sub>-agonist systemic effects compared with healthy subjects. No dose adjustment is required for patients with renal impairment.</p><p>The effects of haemodialysis have not been studied.</p><p>Hepatic Impairment</p><p>Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was an increase in fluticasone furoate systemic exposure (up to three-fold as measured by AUC<sub>(0&ndash;24)</sub>) in subjects with hepatic impairment (Child-Pugh A, B or C) compared with healthy subjects The increase in fluticasone furoate systemic exposure (fluticasone furoate/vilanterol 200/25 micrograms) in subjects with moderate hepatic impairment (Child-Pugh B) was associated with an average 34% reduction in serum cortisol compared with healthy subjects. In subjects with severe hepatic impairment (Child Pugh C) that received a lower dose of 100/12.5 micrograms there was no reduction in serum cortisol. For patients with moderate or severe hepatic impairment the maximum dose is 100/25&nbsp;micrograms (see Dosage and Administration).</p><p>&nbsp;</p><p>Following repeat dosing of fluticasone furoate/vilanterol for 7 days, there was no significant increase in systemic exposure to vilanterol (C<sub>max</sub> and AUC) in subjects with mild, moderate, or severe hepatic impairment (Child-Pugh A, B or C).</p><p>There were no clinically relevant effects of the fluticasone furoate/vilanterol combination on beta-adrenergic systemic effects (heart rate or serum potassium) in subjects with mild or moderate hepatic impairment (vilanterol, 25 micrograms) or with severe hepatic impairment (vilanterol, 12.5 micrograms) compared with healthy subjects.</p><p>Gender, Weight and BMI</p><p>There was no evidence for gender, weight or BMI to influence the pharmacokinetics of fluticasone furoate based on a population pharmacokinetic analysis of phase III data in 1213 subjects with asthma (712 females) and 1225 subjects with COPD (392 females).</p><p>There was no evidence for gender, weight or BMI to influence the pharmacokinetics of vilanterol based on a population pharmacokinetic analysis in 856 subjects with asthma (500 females) and 1091 subjects with COPD (340 females).</p><p>No dosage adjustment is necessary based on gender, weight or body mass index (BMI).</p><p>Clinical Studies</p><p>RELVAR ELLIPTA clinical studies</p><p>Asthma</p><p>The safety and efficacy of fluticasone furoate (FF) and vilanterol (VI) in the treatment of asthma has been evaluated in 3 randomised, double-blind clinical trials of between 12 to 76 weeks in duration (HZA106827, HZA106829 and HZA106837) involving 3,210 patients 12 years of age and older with persistent asthma.</p><p>All subjects were using an ICS (Inhaled Corticosteroid) with or without LABA for at least 12 weeks prior to Visit 1. In HZA106837 all patients had at least one exacerbation that required treatment with oral corticosteroids in the year prior to Visit 1. Results for HZA106827 and HZA106829 are shown in the table below:</p><p>Summary of Data from Studies HZA106829 and HZA106827</p><table border="1" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td style="vertical-align:top"><p><strong>Study No.</strong></p></td><td style="vertical-align:top"><p><strong>HZA106829</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HZA106827</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>RELVAR ELLIPTA 200/25OD*</p><p>vs FF 200 OD</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>RELVAR ELLIPTA 100/25 OD</p><p>vs FF 100 OD</p></td><td style="vertical-align:top"><p>RELVAR</p><p>ELLIPTA 100/25 OD</p><p>vs placebo OD</p></td><td style="vertical-align:top"><p>FF 100 OD vs placebo OD</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Change from Baseline in Trough FEV<sub>1 </sub>(mL)<br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95% CI)</p><p>p-value</p></td><td style="vertical-align:top"><p>193 (108, 277)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>36 (-48, 120)</p><p>p=0.405</p></td><td style="vertical-align:top"><p>172 (87, 258)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>136 mL(51, 222) p=0.002</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Weighted Mean Serial FEV<sub>1</sub> over 0-24 hours post-dose (mL)<br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95% CI)</p><p>p-value</p></td><td style="vertical-align:top"><p>136 (1, 270)</p><p>p=0.048</p></td><td style="vertical-align:top"><p>116 (-5, 236)</p><p>p=0.06</p></td><td style="vertical-align:top"><p>302 (178, 426)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>186 mL(62, 310) p=0.003</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Change from Baseline in Rescue&ndash;free 24 hour periods<br />&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95% CI)</p><p>p-value</p></td><td style="vertical-align:top"><p>11.7% (4.9, 18.4)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>10.6% (4.3, 16.8)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>19.3% (13.0, 25.6)</p><p>p&lt;0.001</p></td><td style="vertical-align:top"><p>8.7% (2.4, 15.0)</p><p>p=0.007</p></td></tr></tbody></table><p>*OD = Once Daily</p><p>&nbsp;</p><p>HZA106837 was of variable treatment duration (from a minimum of 24 weeks to a maximum of 76 weeks with the majority of patients treated for at least 52 weeks) and compared&nbsp; RELVAR ELLIPTA 100/25 micrograms [N=1009] and FF 100 micrograms [N=1010].&nbsp; The primary endpoint was the time to first severe asthma exacerbation (a severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids or an inpatient hospitalization or emergency department visit.</p><p>The risk of experiencing a severe asthma exacerbation in patients receiving RELVAR ELLIPTA 100/25 was reduced by 20% compared with FF 100 alone (hazard ratio 0.795, p=0.036 95% CI (0.642, 0.985)). &nbsp;The rate of severe asthma exacerbations per patient per year was 0.19 in the FF 100 group and 0.14 in the RELVAR ELLIPTA 100/25 group. &nbsp;The ratio of the exacerbation rate for RELVAR ELLIPTA 100/25 versus FF 100 was 0.755 (95% CI 0.603, 0.945).&nbsp; This represents a 25% reduction in the rate of severe asthma exacerbations for subjects treated with RELVAR ELLIPTA 100/25 compared with FF 100 (p=0.014).&nbsp; The 24-hour bronchodilator effect of RELVAR ELLIPTA was maintained throughout a one-year treatment period with no evidence of loss in efficacy (no tachyphylaxis). RELVAR ELLIPTA 100/25&nbsp;micrograms consistently demonstrated 83 mL to 95 mL improvements in trough FEV<sub>1</sub> at Weeks 12, 36 and 52 and Endpoint compared with FF 100 (p&lt;0.001 95% CI 52, 126mL at Endpoint).&nbsp; Forty four percent of patients in the RELVAR ELLIPTA 100/25 group were well controlled (ACQ7 &le;0.75) at end of treatment compared to 36% of subjects in the FF 100 group (p&lt;0.001 95% CI 1.23, 1.82).</p><p><strong><u>Chronic Obstructive Pulmonary Disease </u></strong></p><p>The efficacy of <strong><em>RELVAR ELLIPTA&nbsp;</em></strong>in the treatment of patients with COPD has been evaluated in two 6-month (HZC112206, HZC112207) two one-year randomised controlled studies (HZC102970, HZC102871) , and one long-term study (SUMMIT) in patients with a clinical diagnosis of COPD.</p><p><u>Six month studies</u></p><p>HZC112206 and HZC112207 were 24 week randomised, double-blind, placebo controlled, parallel group studies comparing the effect of the combination to vilanterol and FF alone and placebo.&nbsp; HZC112206 evaluated the efficacy of RELVAR ELLIPTA 50/25 micrograms [n=206] and RELVAR ELLIPTA 100/25 micrograms [n=206]) compared with FF (100 micrograms [n=206]) and vilanterol (25&nbsp;micrograms [n=205]) and placebo (n&nbsp;=&nbsp;207), all administered once daily.</p><p>HZC112207 evaluated the efficacy of RELVAR ELLIPTA 100/25 micrograms [n=204] and RELVAR ELLIPTA 200/25 [n=205]) compared with FF (100 micrograms [n=204] and 200 micrograms [n=203]) and vilanterol (25&nbsp;micrograms [n=203]) and placebo (n&nbsp;=&nbsp;205), all administered once daily.&nbsp;</p><p>The co-primary endpoints in both studies were the weighted mean FEV<sub>1</sub> from zero to 4 hours post-dose and change from baseline in pre-dose trough FEV<sub>1 </sub>at the end of the study.</p><p>In an integrated analysis of both studies, RELVAR ELLIPTA 100/25 micrograms showed clinically meaningful improvements in lung function.&nbsp; At the 24-week time point RELVAR ELLIPTA 100/25 micrograms and vilanterol increased trough FEV<sub>1</sub> by 129 mL (95% CI 91, 167mL, p&lt;0.001) and 83mL (95% CI 46, 121mL, p&lt;0.001) respectively compared with placebo. RELVAR ELLIPTA 100/25&nbsp;micrograms increased trough FEV<sub>1</sub> by 46ml compared with vilanterol (95% CI 8, 83mL, p= 0.017).</p><p>At the 24-week time point RELVAR ELLIPTA 100/25&nbsp;micrograms and vilanterol had a higher weighted mean FEV<sub>1 </sub>over 0-4 hours of 193 mL (95% CI 156, 230mL, p&lt;0.001) and 145 mL (95% CI 108, 181mL, p&lt;0.001) respectively compared&nbsp;with placebo. &nbsp;The difference in weighted mean FEV<sub>1 </sub>over 0-4 hours between the fluticasone furoate/vilanterol 100/25 and vilanterol groups<strong> </strong>was 48 mL (95% CI 12, 84 mL, p= 0.009).</p><p><u>12 months studies</u></p><p>Studies HZC102970 and HZC102871 were 52 week randomised, double-blind, parallel-group, studies comparing the efficacy and safety of RELVAR ELLIPTA 200/25&nbsp;micrograms, RELVAR ELLIPTA 100/25&nbsp;micrograms, fluticasone furoate/vilanterol 50/25 micrograms and vilanterol 25 micrograms, all administered once daily. The primary endpoint was the reduction in the annual rate of moderate and severe exacerbations in subjects with COPD.&nbsp;</p><p>The results of both studies showed that treatment with RELVAR ELLIPTA 100/25&nbsp;micrograms once daily resulted in a 27% reduction in the annual rate of moderate or severe COPD exacerbations compared with vilanterol (95% CI:16, 37% (p&le;0.001). Reductions in risk of time to first moderate or severe exacerbation and rate of exacerbations requiring corticosteroid use were also observed with fluticasone furoate/vilanterol 100/25&nbsp;micrograms once daily compared with vilanterol.</p><p>In a pooled analysis of HZC102970 and HZC102871, at Week 52, the RELVAR ELLIPTA 100/25&nbsp;microgram&nbsp; group demonstrated greater improvement in trough FEV<sub>1</sub> compared with the vilanterol 25 microgram group (a difference of 42&nbsp;mL in adjusted mean change from baseline;95% CI: 19, 64mL, p&lt;0.001).</p><p><u>Long-term study</u></p><p>SUMMIT was a multi-centre, randomised, double-blind study evaluating the effect on survival of RELVAR ELLIPTA 100/25 micrograms compared with placebo in 16,568&nbsp;subjects. Subjects were treated for up to 4&nbsp;years (mean 1.7&nbsp;years) with either RELVAR ELLIPTA 100/25 micrograms, fluticasone<u> </u>furoate 100&nbsp;micrograms, vilanterol&nbsp;25&nbsp;micrograms, or placebo. All subjects had COPD with moderate airflow limitation (&ge;50% and &le;70% predicted FEV<sub>1</sub>) and a history of, or an increased risk of, cardiovascular disease.</p><p>Survival with RELVAR ELLIPTA was not significantly improved compared with placebo (HR 0.878; 95% CI: 0.739, 1.042; p=0.137), FF (HR 0.964; 95% CI: 0.808, 1.149; p=0.681) or VI (HR 0.912; 95% CI: 0.767, 1.085; p=0.299). All-cause mortality was: fluticasone furoate/vilanterol, 6.0%; placebo, 6.7%; fluticasone furoate, 6.1%; vilanterol, 6.4%).&nbsp;</p><p>RELVAR ELLIPTA slowed the rate of decline in lung function as measured by FEV<sub>1</sub>, by 8 mL/year compared with placebo (95% CI: 1, 15; p=0.019). There was no impact (0 mL/year; 95% CI: -6, 7; p=0.913) on the rate of decline for RELVAR ELLIPTA compared with fluticasone furoate; there was a difference of 10 mL/year for RELVAR ELLIPTA compared with vilanterol (95% CI: 3, 16; p=0.004). The mean rate of decline in FEV<sub>1</sub> was: RELVAR ELLIPTA, 38 mL/year; placebo, 46 mL/year; fluticasone furoate, 38 mL/year; vilanterol, 47 mL/year.</p><p>The risk of a cardiovascular composite event (on-treatment cardiovascular death, myocardial infarction, stroke, unstable angina, or transient ischemic attack) with RELVAR ELLIPTA was not significantly lower than placebo (HR 0.926; 95%&nbsp;CI: 0.750, 1.143; p=0.475), FF (HR 1.033; 95%&nbsp;CI: 0.834, 1.281; p=0.763) or VI (HR 0.938; 95%&nbsp;CI: 0.761, 1.155; p=0.545). The incidence of cardiovascular composite events was: RELVAR ELLIPTA, 4.2%; placebo, 4.2%; fluticasone furoate, 3.9%; vilanterol 4.4%.</p><p>RELVAR ELLIPTA demonstrated a larger mean change from baseline in post-bronchodilator FEV<sub>1</sub> at Day 360 compared with placebo (89&nbsp;mL; 95%&nbsp;CI: 76, 102; p&lt;0.001), FF (40&nbsp;mL; 95%&nbsp;CI: 27, 53; p&lt;0.001), and VI (26&nbsp;mL; 95%&nbsp;CI: 13, 39; p&lt;0.001). The adjusted mean change from baseline was: RELVAR ELLIPTA&nbsp; 50&nbsp;mL, placebo, ‑39&nbsp;mL; fluticasone furoate, 9&nbsp;mL; vilanterol, 24&nbsp;mL.</p><p>RELVAR ELLIPTA reduced the annual rate of moderate or severe exacerbations by 29% (95%&nbsp;CI: 22, 35; p&lt;0.001) compared with placebo, by 19% compared with FF (95%&nbsp;CI: 12, 26; p&lt;0.001) and by 21% compared with VI (95%&nbsp;CI: 14, 28; p&lt;0.001). The annual rate of moderate or severe exacerbations was 0.25 for RELVAR ELLIPTA, 0.35 for placebo, 0.31 for fluticasone furoate, and 0.31 for vilanterol.</p><p>RELVAR ELLIPTA reduced the annual rate of severe exacerbations (i.e.&nbsp;requiring hospitalisation) by 27% (95%&nbsp;CI: 13, 39; p&lt;0.001) compared with placebo, by 11% compared with FF (95%&nbsp;CI: -6, 25; p=0.204) and by 9% compared with VI (95%&nbsp;CI: -8, 24; p=0.282). The annual rate of exacerbations requiring hospitalisation was 0.05 for RELVAR ELLIPTA, 0.07 for placebo, 0.06 for fluticasone furoate, and 0.06 for vilanterol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacological and toxicological effects seen with fluticasone furoate or vilanterol in nonclinical studies were those typically associated with either glucocorticoids or beta<sub>2</sub>-agonists. Administration of fluticasone furoate combined with vilanterol did not result in any significant new toxicity.</p><p>Carcinogenesis/mutagenesis</p><p>Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures similar to those at the maximum recommended human dose, based on AUC.</p><p>Genetic toxicity studies indicate vilanterol does not represent a genotoxic hazard to humans. Consistent with findings for other beta<sub>2</sub>-agonists, in lifetime inhalation studies vilanterol caused proliferative effects in the female rat and mouse reproductive tract and rat pituitary gland. There was no increase in tumour incidence in rats or mice at exposures 2- or 30-fold, respectively, those at the maximum recommended human dose, based on AUC.</p><p>Reproductive Toxicology</p><p>Effects seen following inhalation administration of fluticasone furoate in combination with vilanterol in rats were similar to those seen with fluticasone furoate alone.</p><p>Fluticasone furoate was not teratogenic in rats or rabbits, but delayed development in rats and caused abortion in rabbits at maternally toxic doses. There were no effects on development in rats at exposures approximately 3-times greater than those at the maximum recommended human dose, based on AUC.</p><p>Vilanterol was not teratogenic in rats. In inhalation studies in rabbits, vilanterol caused effects similar to those seen with other beta<sub>2</sub>-agonists (cleft palate, open eyelids, sternebral fusion and limb flexure/malrotation). When given subcutaneously there were no effects at exposures 84‑times greater than those at the maximum recommended human dose, based on AUC.</p><p>Neither fluticasone furoate nor vilanterol had any adverse effects on fertility or pre- and post-natal development in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate (which contains milk protein)<br />(12.5 milligram lactose monohydrate per blister)</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
In-use shelf-life
Following removal from the tray, the product may be stored for a maximum period of: 
1 month: below 30°C
Write the date the inhaler should be discarded on the label in the space provided. The date should be added as soon as the inhaler has been removed from the tray.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Storage condition depends on local registration requirements.</p><p>Store below 30&deg;C</p><p>If stored in the refrigerator, allow the inhaler to return to room temperature for at least an hour before use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The plastic Ellipta inhaler consists of a light grey body, a pale blue or yellow mouthpiece cover and a dose counter, packed into a foil laminate tray containing a desiccant<strong><s> </s>sachet</strong>.&nbsp; The tray is sealed with a peelable foil lid.&nbsp;</p><p>The inhaler contains two strips of 14 or 30 regularly distributed blisters, each containing a white powder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When you first use the Ellipta inhaler you do not need to check that it is working properly. It is ready for use straightaway, and you do not need to prepare it for use in any special way. Just follow these step-by-step instructions.</p><p><strong>Your Ellipta inhaler carton contains</strong></p><p><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="img1.jpg" style='width:256pt;height:212pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="img1"/>
</v:shape><![endif]--><img width="341" height="283" alt="img1.jpg" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>The inhaler is packaged in a tray<strong>.</strong> <strong>Do not open the tray</strong> until you are ready to inhale a dose of your medicine.&nbsp; When you are ready to use your inhaler, peel back the lid to open the tray. The tray contains a desiccant sachet, to reduce moisture. Throw this dessicant sachet away &mdash; <strong>don&rsquo;t</strong> <strong>open, </strong>eat or inhale it.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;margin-left:157.55pt;margin-top:0;width:159pt;
 height:159pt;z-index:251658240'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="212" height="212" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><strong><!--[if gte vml 1]><v:shape
 id="Picture_x0020_4" o:spid="_x0000_i1026" type="#_x0000_t75" alt="Fig A"
 style='width:157.5pt;height:157.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title="Fig A"/>
</v:shape><![endif]--><img width="210" height="210" alt="Fig A" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></strong></p><p>When you take the inhaler out of its box, it will be in the &lsquo;closed&rsquo; position. <strong>Don&rsquo;t open the inhaler </strong>until you are ready to inhale a dose of medicine. Write the &ldquo;Discard by&rdquo; date on the inhaler label in the space provided.</p><p>The step-by-step instructions shown below for the 30-dose (30 day supply) Ellipta inhaler also apply to the 14‑dose (14 day supply) Ellipta inhaler.</p><p>&nbsp;</p><p><strong>a)&nbsp;&nbsp;&nbsp; </strong><strong>Read this before you start</strong></p><p>If you open and close the cover without inhaling the medicine, you will lose the dose.</p><p>The lost dose will be securely held inside the inhaler, but it will no longer be available.</p><p>It is not possible to accidentally take extra medicine or a double dose in one inhalation.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:300.5pt;height:211.5pt'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title="Ellipta_step1_diag"/>
</v:shape><![endif]--><img width="401" height="282" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg" /></p><p>&nbsp;</p><p><strong>b)&nbsp;&nbsp;&nbsp; </strong><strong>Prepare a dose </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait to open the cover until you are ready to take your dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake the inhaler.</p><p>&middot;&nbsp;&nbsp; Slide the cover down until you hear a &ldquo;click&rdquo;.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:267pt;height:196.5pt'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title="Ellipta_step2_diag"/>
</v:shape><![endif]--><img width="356" height="262" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></p><ul><li>Your medicine is now ready to be inhaled.</li><li>The dose counter counts down by <strong>1</strong> to confirm.</li></ul><ul><li>If the dose counter does not count down as you hear the &ldquo;click&rdquo;, the inhaler will not deliver medicine. Take it back to your pharmacist for advice.</li><li>Do not shake the inhaler at any time</li></ul><p>&nbsp;</p><p><strong>c)&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Inhale your medication</strong></p><ul><li>While holding the inhaler away from your mouth, breathe out as far as is comfortable.</li><li>Don&rsquo;t<strong><s> </s></strong>breathe out into the inhaler.</li><li>Put the mouthpiece between your lips and close your lips firmly around it.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t<s> </s>block the air vent with your fingers.</li></ul><p><strong>&nbsp;</strong></p><p><strong><s>&nbsp;</s></strong></p><p><strong><!--[if gte vml 1]><v:shape id="Picture_x0020_1"
 o:spid="_x0000_i1029" type="#_x0000_t75" style='width:300pt;height:157pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
  o:title="" chromakey="#efefef"/>
</v:shape><![endif]--><img width="400" height="209" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /></strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one long, steady, deep breath in. Hold this breath for as long as possible (at least 3-4 seconds).</p><ul><li>Remove the inhaler from your mouth.</li><li>Breathe out slowly and gently.</li></ul><p>You may not be able to taste or feel the medicine, even when you are using the inhaler correctly.</p><p>If you want to clean the mouthpiece, use a dry tissue, before you close the cover.</p><p>&nbsp;</p><p><strong>(d) Close the inhaler and rinse your mouth </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slide the cover upwards as far as it will go, to cover the mouthpiece.</p><p><strong>&nbsp;</strong></p><p><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1030" type="#_x0000_t75" style='width:249.5pt;height:258.5pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image013.png"
  o:title=""/>
</v:shape><![endif]--><img width="333" height="345" src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /></strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse your mouth with water after you have used the inhaler.</p><p>This will make it less likely that you will develop a sore mouth or throat as side effects.</p><p>Not all presentations are available in every country.</p><p>Relvar Ellipta are trademarks owned by GSK group of companies. Relvar Ellipta was developed in collaboration with Innoviva, Inc.</p><p>&copy; 20<strong><em>22</em></strong> GSK group of companies, all rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Glaxo Operations UK Limited, Ware*, Hertfordshire, UK 
Marketing Authorisation Holder: 
Glaxo Saudi Arabia Limited, Jeddah*, Saudi Arabia 
*member of the GlaxoSmithKline group of companie

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number:  GDS12/IPI12
Date of issue: 27 May 2021 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>